Table 2.
Overview of AC Indications and Characteristics
| Study | Indications for Anticoagulation (%)a | Received AC | AC type | Time to Restarting AC (days) | |||||
|---|---|---|---|---|---|---|---|---|---|
| NVAF | Prosthetic heart valve | VTE | Prior stroke | Recent MI | Other | ||||
| De Vleeschouwer et al17 | 56 (51.9) | 30 (27.8) | 11 (10.2) | 4 (3.7) | 2 (1.9) | 5 (4.6) | 25 (23.1) | VKA | 11 |
| Classen et al18 | 23 (47.9) | 12 (25.0) | 10 (20.8) | N/A | N/A | 3 (6.3) | 23 (47.9) | VKA (Warfarin) | 10 |
| Majeed et al20 | 135 (58.0) | 35 (15.0) | 37 (16.0) | N/A | N/A | 27 (11.0) | 45 (34.1)b | VKA (Warfarin) | 39.2 |
| Yung et al19 | 191 (67.3) | 37 (13.0) | 31 (10.9) | N/A | N/A | N/A | 91 (32.0) | VKA (Warfarin) | N/A |
| Gathier et al12 | 10 (40.0) | 2 (8.0) | 6 (24.0) | 8 (32.0) | 2 (8.0) | 4 (16.0) | 12 (48.0) | VKA | Within 2 months |
| Nielsen et al16 | 1,752 (100.0) | 0 | 0 | 0 | 0 | 0 | 509 (29.1) | VKA/NOAC | N/A |
| Kuramatsu et al11 | 664 (77.8) | 67 (7.9) | 71 (8.3) | N/A | N/A | 51 (6.0) | 172 (23.9) | VKA | 31 |
| Ottosen et al15 | 1,032 (34.7) | 78 (2.6) | 236 (7.9) | 2,139 (71.8) | 264 (8.9) | 30 (1.0) | 160 (6.3)c | VKA/NOAC | Within first 6 months |
Abbreviations: AC, anticoagulant therapy; NOAC, non-vitamin K oral anticoagulant medications; VKA, vitamin K antagonists
a
sum of all indications may exceed 100% since some patients had multiple indications for AC
b
data on 132 patients with cardiac indications who were restarted on AC was available
c
data was available on 2543 patients who survived.